Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim for Prevention of Severe Chemotherapy Induced Thrombocytopenia in Lymphoma Patients
NCT04673266Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2020
- Primary completion
- Apr 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of romiplostim in chemotherapy-induced thrombocytopenia (CIT), sponsored by Memorial Sloan Kettering Cancer Center. Started Dec 2020; status: completed.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT04673266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04673266.